Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study
Purpose. Dry eye disease (DED) can be triggered using preserved ophthalmic formulations or prostaglandin analogs. In this prospective, nonrandomized, open-label pilot study, we evaluated the efficacy of a 0.15% hyaluronic acid (HA) nonpreserved ophthalmic formulation in decreasing DED symptoms in pa...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2022/1320996 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552901974687744 |
|---|---|
| author | Giulia Coco Danilo Iannetta Igino Febbraro Ester Elmo Gianluca Manni |
| author_facet | Giulia Coco Danilo Iannetta Igino Febbraro Ester Elmo Gianluca Manni |
| author_sort | Giulia Coco |
| collection | DOAJ |
| description | Purpose. Dry eye disease (DED) can be triggered using preserved ophthalmic formulations or prostaglandin analogs. In this prospective, nonrandomized, open-label pilot study, we evaluated the efficacy of a 0.15% hyaluronic acid (HA) nonpreserved ophthalmic formulation in decreasing DED symptoms in patients with open-angle glaucoma treated with prostaglandin analogs. Methods. 30 patients with DED receiving chronic treatment with prostaglandin analogs for primary open-angle glaucoma or ocular hypertension were administered ophthalmic formulations 3 times daily for 12 weeks. Foreign body sensation, burning, stinging, dryness, pain, frequency of symptoms, Ocular Surface Disease Index (OSDI), conjunctival hyperaemia, corneal fluorescein staining (CFS), tear film break-up time (TBUT), best-corrected visual acuity, Schirmer test results, and 25-item National Eye Institute Visual Function Questionnaire score between the baseline and 4 and 12 weeks were evaluated. Results. The analysis shows that all primary endpoints improved; in particular, burning sensation and the frequency of symptoms after 4 and 12 weeks of treatment (p<0.001) and dryness and pain after 12 weeks of treatment (p<0.001 and p=0.03, respectively) were reduced significantly. Secondary outcomes confirmed the positive results, with a statistically significant change in the OSDI score and CFS between the baseline and 4 (p=0.02 and p<0.001, respectively) or 12 weeks (both p<0.001) and TBUT after 4 weeks (p=0.01). Conjunctival hyperaemia improved in both eyes in >90% of cases at 12 weeks of treatment. Conclusion. The present study shows that the ophthalmic formulation containing 0.15% HA has a promising beneficial effect on reducing the signs and symptoms of DED in patients treated with prostaglandin analogs. |
| format | Article |
| id | doaj-art-2c0f06e1f5934bd08d3ba9fcf675baeb |
| institution | Kabale University |
| issn | 2090-0058 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-2c0f06e1f5934bd08d3ba9fcf675baeb2025-02-03T05:57:26ZengWileyJournal of Ophthalmology2090-00582022-01-01202210.1155/2022/1320996Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot StudyGiulia Coco0Danilo Iannetta1Igino Febbraro2Ester Elmo3Gianluca Manni4Department of Clinical Sciences and Translational MedicineOphthalmology UnitDepartment of Clinical Sciences and Translational MedicineDepartment of Clinical Sciences and Translational MedicineDepartment of Clinical Sciences and Translational MedicinePurpose. Dry eye disease (DED) can be triggered using preserved ophthalmic formulations or prostaglandin analogs. In this prospective, nonrandomized, open-label pilot study, we evaluated the efficacy of a 0.15% hyaluronic acid (HA) nonpreserved ophthalmic formulation in decreasing DED symptoms in patients with open-angle glaucoma treated with prostaglandin analogs. Methods. 30 patients with DED receiving chronic treatment with prostaglandin analogs for primary open-angle glaucoma or ocular hypertension were administered ophthalmic formulations 3 times daily for 12 weeks. Foreign body sensation, burning, stinging, dryness, pain, frequency of symptoms, Ocular Surface Disease Index (OSDI), conjunctival hyperaemia, corneal fluorescein staining (CFS), tear film break-up time (TBUT), best-corrected visual acuity, Schirmer test results, and 25-item National Eye Institute Visual Function Questionnaire score between the baseline and 4 and 12 weeks were evaluated. Results. The analysis shows that all primary endpoints improved; in particular, burning sensation and the frequency of symptoms after 4 and 12 weeks of treatment (p<0.001) and dryness and pain after 12 weeks of treatment (p<0.001 and p=0.03, respectively) were reduced significantly. Secondary outcomes confirmed the positive results, with a statistically significant change in the OSDI score and CFS between the baseline and 4 (p=0.02 and p<0.001, respectively) or 12 weeks (both p<0.001) and TBUT after 4 weeks (p=0.01). Conjunctival hyperaemia improved in both eyes in >90% of cases at 12 weeks of treatment. Conclusion. The present study shows that the ophthalmic formulation containing 0.15% HA has a promising beneficial effect on reducing the signs and symptoms of DED in patients treated with prostaglandin analogs.http://dx.doi.org/10.1155/2022/1320996 |
| spellingShingle | Giulia Coco Danilo Iannetta Igino Febbraro Ester Elmo Gianluca Manni Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study Journal of Ophthalmology |
| title | Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study |
| title_full | Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study |
| title_fullStr | Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study |
| title_full_unstemmed | Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study |
| title_short | Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study |
| title_sort | efficacy of nonpreserved sodium hyaluronate artificial tears in dry eye disease patients treated with prostaglandin analogs for primary open angle glaucoma a prospective nonrandomized open label pilot study |
| url | http://dx.doi.org/10.1155/2022/1320996 |
| work_keys_str_mv | AT giuliacoco efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy AT daniloiannetta efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy AT iginofebbraro efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy AT esterelmo efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy AT gianlucamanni efficacyofnonpreservedsodiumhyaluronateartificialtearsindryeyediseasepatientstreatedwithprostaglandinanalogsforprimaryopenangleglaucomaaprospectivenonrandomizedopenlabelpilotstudy |